Navigation Links
New frontiers of fecal microbiota transplantation
Date:8/14/2014

Bethesda, MD (Aug. 14, 2014) Fecal microbiota transplantation (FMT) is one of the most innovative new treatments of the 21st century. Experts believe that this procedure, which transplants microbes from one human gut to another through fecal matter, could offer the cure to a vast range of diseases and shed new light on the role of the microbiome in gastrointestinal diseases. New research presented this weekend at the American Gastroenterological Association's 2014 James W. Freston Conference in Chicago, IL, highlights significant advances in this field, and confirms the promise of FMT to advance our understanding of GI disease and aid in the development of new microbiome-based therapeutics to treat a broad range of GI disorders.

"The 2014 AGA James W. Freston Conference promises to be an important and stimulating meeting in microbiome and FMT research and technology," said course directors Stacy A. Kahn, MD, and David T. Rubin, MD, AGAF, both from The University of Chicago Medicine. "This is the first international conference on FMT and brings together leaders from across the field and will highlight advances in basic science and clinical research. In addition, the conference will also create a forum to discuss the ethical and regulatory issues in this emerging field."

FMT Beyond C. Difficile

While FMT has been proven to be safe and effective for patients with recurrent C. difficile infection, its efficacy in treating other diseases is still in question. Data presented at the AGA James W. Freston Conference will provide evidence that FMT is an effective treatment for a range of other GI disorders. One study reports that 70 percent of subjects who received FMT for refractory irritable bowel syndrome (IBS) had a resolution and/or improved symptoms. Patients reported improved abdominal pain (72 percent), bowel habit (69 percent), dyspepsia (67 percent), bloating (50 percent) and flatus (42 percent). Quality of life was also improved in 46 percent of patients.

Data also confirm the potential for FMT in treating inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease. A study out of Montefiore Medical Center finds that colonoscopic FMT, followed by self-administered fecal enemas, resulted in improved symptoms and decreased medication requirements, especially in IBD patients with concomitant C. difficile infection.

On the Horizon: Orally Delivered Microbes

FMT has multiple liabilities, including invasive delivery, cost and complexity of donor management, variability of FMT preparation, and the potential to transmit pathogens. A new study, to be presented at the meeting, holds the answer to these challenges an orally delivered community of microbes. SER---109, developed by Seres Health, Inc., proved to be remarkably efficacious and safe with a 100 percent cure rate for the treatment of recurrent C. difficile infection in the study population. The pill works to rapidly repair the microbial imbalance cause by chronic antibiotic treatment for C. difficile by inducing the formation of a diverse and healthy microbiome. This pill has the potential to replace FMT and maximize utility for clinicians and patients.

New Understanding of the FMT Patient

Due to the "yuck" factor, some patients and clinicians are reluctant to consider FMT. New data to be presented at the AGA James W. Freston Conference sheds light on the factors that lead to acceptance of FMT. The study found that patients who have children are more likely to accept FMT, suggesting that parents may be more willing to try emerging procedures for the sake of their children. Having a college degree was also a significant factor, implying that a better understanding of the disease may affect one's willingness to undergo FMT. The main concern for undergoing FMT was the risk of disease transmission. Since FMT is a potentially life-saving procedure, medical practitioners should use this knowledge when counseling patients and their families on the decision to undergo FMT.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers working at frontiers of melanoma research
2. Frontiers launches new open-access journal: Frontiers in Pediatrics
3. Frontiers publishes systematic review on the effects of yoga on major psychiatric disorders
4. Moffitt Cancer Center researchers discuss new frontiers in breast cancer screening
5. Shopping Cart Software Provider, Shopping Cart Elite Officially Launches Greenfrontierswater.com
6. DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation
7. DIA to Host Annual Canadian Meeting: New Realities/New Frontiers
8. Caring for patients with fecal incontinence costs more than $4,000 per person each year
9. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
10. Fecal Transplant to Cure Gut Infection?
11. Fecal microbiota transplantation cures gastrointestinal diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology: